目的调查鲍氏不动杆菌的流行情况、耐药性,并探讨治疗用药。方法采用回顾性方法统计分析某三级甲等医院2007-2009年检出的鲍氏不动杆菌的标本来源、感染科室分布及耐药状况。结果鲍氏不动杆菌阳性检出率近2年来明显增加;其最常出现在痰标本中,占95.24%;表现为高度耐药和多药耐药,对亚胺培南耐药率为66.82%,且呈不断上升趋势,差异有统计学意义(P<0.05);亚胺培南耐药菌株多分布在ICU占52.34%,其次是呼吸病房占23.83%;对鲍氏不动杆菌耐药率最低的抗菌药物是多黏菌素,耐药率为0;其他依次是头孢哌酮/舒巴坦1.45%、米诺环素7.09%、阿米卡星50.17%。结论鲍氏不动杆菌已是呼吸道感染最常见的细菌之一,其耐亚胺培南菌株的不断增多,使抗菌药物面临着选择压力;治疗上可考虑联合应用头孢哌酮/舒巴坦、米诺环素、阿米卡星。 Objective To investigate the prevalence of Acinetobacter baumannii, drug resistance and to explore the therapeutic drug. Methods The retrospective method was used to statistically analyze the source of specimens of Acinetobacter baumannii from 2007 to 2009 in a third class Hospitals and the distribution and drug resistance of the infected departments. Results The positive rate of Acinetobacter baumannii was significantly increased in the past two years. It was most frequently found in sputum samples, accounting for 95.24%. The drug resistance was high and multi-drug resistant. The resistance rate to imipenem was 66.82 %, And showed a rising trend, the difference was statistically significant (P <0.05); imipenem resistant strains were mostly distributed in ICU accounting for 52.34%, followed by respiratory ward accounted for 23.83%; resistant to Acinetobacter baumannii The lowest antibacterial drug was polymyxin, and the resistance rate was 0; the others were cefoperazone / sulbactam 1.45%, minocycline 7.09% and amikacin 50.17%. Conclusion Acinetobacter baumannii is one of the most common bacteria in respiratory tract infection, its resistance to imipenem strains continue to increase, so that antibiotics are faced with selective pressure; treatment may be considered in combination with cefoperazone / sulbactam, Minocycline, Amikacin.